97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details
臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-004303-19-BE (EUCTR)  | 08/06/2007 | 07/02/2007 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes  | 135 | Czech Republic;United Kingdom;Belgium | |||
| 2 | EUCTR2006-006319-54-BE (EUCTR)  | 24/05/2007 | 08/02/2007 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes  | 135 | United Kingdom;Belgium | |||
| 3 | EUCTR2006-006319-54-CZ (EUCTR)  | 14/05/2007 | 20/02/2007 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes  | 135 | Phase 2 | Czech Republic;Belgium;United Kingdom | ||
| 4 | EUCTR2006-004303-19-CZ (EUCTR)  | 09/05/2007 | 20/02/2007 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes  | 181 | United Kingdom;Czech Republic;Belgium | |||
| 5 | EUCTR2006-006319-54-SK (EUCTR)  | 07/05/2007 | 08/03/2007 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes  | 135 | Phase 2 | Czech Republic;Slovakia;Belgium;United Kingdom | ||
| 6 | EUCTR2006-004303-19-SK (EUCTR)  | 04/05/2007 | 08/03/2007 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes  | 181 | Phase 2 | Czech Republic;Slovakia;Belgium;United Kingdom | ||
| 7 | EUCTR2006-006319-54-GB (EUCTR)  | 25/04/2007 | 07/12/2006 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | An Open Label Evaluation of the Safety and Efficacy of Basiliximab Maintenance in Ulcerative Colitis - BSX-002 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting |  Female: yes Male: yes  | 135 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Czech Republic;Slovakia;Belgium;United Kingdom | ||
| 8 | EUCTR2006-004303-19-GB (EUCTR)  | 25/04/2007 | 06/12/2006 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulcerative Colitis - BSX-001 | Steroid-refractory ulcerative colitis  MedDRA version: 8.1;Level: LLT;Classification code 10009900;Term: Colitis ulcerative  | Trade Name: Simulect Product Name: Basiliximab Other descriptive name: Basiliximab  | Cerimon Pharmaceuticals, Inc. | NULL | Not Recruiting | Female: yes Male: yes  | 135 | Phase 2 | Czech Republic;Slovakia;Belgium;United Kingdom |